In FY17, the company’s revenue from the pharma business came in at ~Rs4,054cr. Of this, Rs3,517cr came in from the Global Pharma business and Rs537 came in from the Indian Consumer Products business. The company’s revenue from pharma has grown by 17% CAGR from FY11-17 and is expected to reach Rs6,500-7,000 by FY20.
Piramal Enterprises Ltd is currently trading at Rs 2824, up by Rs 49.25 or 1.77% from its previous closing of Rs 2774.75 on the BSE. The stock touched a 52 week high of Rs 3083.05 on 13-Jun-2017 and a 52 week low of Rs 1443.9 on 26-Dec-2016. Last one week high and low of the scrip stood at Rs 2817.65 and Rs 2587.8 respectively.